Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

Medical Behemoth AstraZeneca Flirts With Breakout On Fresh Hope In Ovarian Cancer

AstraZeneca said Wednesday a combination of its drugs Lynparza and Imfinzi met the goal of a key study, leading AZN stock to surge.

Investors Business Daily

Airplanes face a growing risk of being hit by uncontrolled re-entries of rockets used to launch satellites

On May 11, 2020 a deadly threat flew from Los Angeles to New York City in under nine minutes. It was a 20-tonne Chinese Long March 5B rocket body passing around 60 miles overhead.

The Conversation

Jeremy Hunt aims to spur business investment with ‘full expensing’ tax break

Measure over next three years will allow firms to write off costs of IT equipment and machinery against tax on profits

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Thousands still waiting for Covid jab payout as over £5million paid in damages so far

Under the Vaccine Damage Payment Scheme, those harmed by the coronavirus jab get a £120,000 payment but thousands are still waiting for their claims to be assessed

Daily Mirror

Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race

Sanofi stock could shine in 2023 as the French pharma tees up a rival to Pfizer's experimental RSV vaccine for newborn babies.

Investors Business Daily

The Best Stock to Buy for Under $100 Right Now

Strong fundamentals and bright prospects of AstraZeneca (AZN), trading below $100 a share, could help investors secure decent risk-adjusted returns on their investments in a choppy market environment. Read on….

StockNews.com

AstraZeneca's Trading Range Makes This Options Trade Appealing

AztraZeneca (AZN), a U.K. developer of branded prescription therapeutics, ranks first in IBD's diversified medical industry group. But the Composite Rating is only 63. This, combined with the weakening of the market, makes this a solid choice for our familiar short iron condor. With the suspicion that the markets are…

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Rishi Sunak faces Tory Budget rebellion over corporation tax REDIRECTED

Leaders of Tory several factions write to PM urging rethink

The Independent UK

Kwasi Kwarteng STILL supports 'general direction' of his economy-destroying mini budget

Former Chancellor of the Exchequer Kwasi Kwarteng is sticking by the "general direction" of his mini budget that crashed the UK economy, but admits that he has regrets

Daily Mirror

RMT strikes to continue, says Mick Lynch, after members reject ‘dreadful’ pay offers – as it happened

RMT general secretary says members could not accept offer he says would make railways less safe

The Guardian - UK

Take AstraZeneca’s warning seriously. The UK is missing out in life sciences

Big pharma has choices about where to make new investments and, increasingly it seems, it is not choosing Britain

The Guardian - UK

AstraZeneca Hits Its Stride On Upbeat Guidance With 'Desirable' Growth

AstraZeneca's earnings topped forecasts Thursday, but sales came in light. AZN stock rose on its upbeat 2023 guidance.

Investors Business Daily

Dow Jones Rallies 250 Points After Jobless Claims; Disney Surges On Earnings

The Dow Jones rallied 250 points Thursday after weekly first-time jobless claims. Disney shares surged on earnings results.

Investors Business Daily

End of vaccine boost for AstraZeneca as it looks elsewhere for growth

The firm made just shy of $4 billion from sales of its Covid-19 vaccine in 2021, but sales have since more than halved and were down 95% at the tail end of last year

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

FTSE 100 Live: Unilever price warning, AstraZeneca and BAT post results

Blue-chip companies Unilever, AstraZeneca and British American Tobacco today lead a busy session for end-of-year corporate earnings.

Salon

A technicality could withhold RSV shots

A glitch in a law may make it difficult for children from low-income families to get the new RSV vaccine

WEKU

A single-shot treatment to protect infants from RSV may be coming soon

The illness sends tens of thousands of babies to the hospital each year. If approved, the new injection would be the first broadly available prevention tool.

ABC News

Health department reviewing fifth COVID-19 vaccine. But what if you have missed a dose?

The health department is expected to make a decision on the fifth dose within weeks. Here's what we know so far.

Get all your
news in one place.

100’s of premium titles.
One news app.

ABC News

ATAGI is considering a fifth COVID-19 vaccine dose, but how many boosters should I already have and who is eligible?

The federal government is waiting on advice about whether Australians should have a fifth COVID-19 vaccine. So, how many people have had the current boosters and who is eligible for what?

Wales Online

How anti-vaccine misinformation hampers conversation about genuine concerns

With more than 13 billion doses administered to date, we know Covid vaccines are overwhelmingly safe, effective,

The Conversation

Andrew Bridgen: how anti-vaccine misinformation hampers the conversation about genuine vaccine injuries

MP Andrew Bridgen was suspended from the Conservative party on January 11 for persistent misinformation about COVID vaccines, including numerous false claims around their safety. The final straw appears to have been his comments comparing the vaccination programme to the Holocaust.

Investors Business Daily

Stock Market Holds Gains; Chip Stock Breaks Out

The stock market held afternoon gains as a server and storage stock flashed a sell signal. Air pollution control stock broke out of a base.

Investors Business Daily

AstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor Buyout

AstraZeneca stock briefly broke out on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor.

Investors Business Daily

AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal

AstraZeneca said it has agreed to buy CinCor Pharma, maker of clinical-stage blood pressure drug baxdrostat, in a deal valued at $1.8 billion.

AFP

AstraZeneca buys US biotech firm CinCor

London (AFP) - Anglo-Swedish pharmaceuticals giant AstraZeneca on Monday agreed to buy US biotech company CinCor for $1.8 billion, expanding further into the field of heart and kidney drugs.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Office for National Statistics

1,955 stories

Pfizer

1,847 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.